Edition:
United States

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
15 Dec 2017
Change (% chg)

$-0.01 (-1.21%)
Prev Close
$0.93
Open
$0.95
Day's High
$0.98
Day's Low
$0.92
Volume
104,405
Avg. Vol
313,902
52-wk High
$14.24
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering​
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Interpace Diagnostics Group Inc -:Interpace Diagnostics Group Inc- ‍New York State Department Of Health has reviewed and approved for marketing co's TERT service offering​.  Full Article

Interpace Diagnostics says Q3 sales up 27 pct
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Interpace Diagnostics Group Inc ::Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments.Q3 sales rose 27 percent to $4.2 million.Interpace diagnostics group inc qtrly ‍net loss per diluted share of common stock $0.15​.  Full Article

Interpace Diagnostics ‍launches new lung cancer test MVPdX​
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics Group Inc - ‍Launch of a new lung cancer test MVPdX​.  Full Article

Interpace Diagnostics reports Q2 ‍loss per share from cont ops of $0.65
Thursday, 10 Aug 2017 09:50am EDT 

Aug 10 (Reuters) - Interpace Diagnostics Group Inc ::Interpace Diagnostics Group reports second quarter 2017 financial results, business progress and recent accomplishments.Qtrly ‍loss per share from continuing operations​ $0.65.Qtrly revenue $3.9 million versus $3.6 million​‍​.Qtrly net loss per diluted share of common stock $0.65​.  Full Article

Interpace Diagnostics says Cigna agreed to cover co's ThyGenx test for Cigna members
Thursday, 27 Jul 2017 08:00am EDT 

July 27 (Reuters) - Cigna Corp :Interpace diagnostics group inc - cigna agreed to cover interpace's thygenx test for cigna members nationwide, with coverage effective immediately.  Full Article

Interpace Diagnostics announces national contract with Aetna
Wednesday, 28 Jun 2017 08:15am EDT 

June 28 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics announces national contract with Aetna.Interpace Diagnostics Group -Signed new national contract with Aetna for its THYGENX and Thyramir molecular tests for indeterminate thyroid nodules​.  Full Article

Interpace Diagnostics announces pricing
Friday, 16 Jun 2017 09:00am EDT 

June 16 (Reuters) - Interpace Diagnostics Group Inc ::Interpace Diagnostics announces pricing of $13.7 million underwritten public offering of common stock and common warrants.Interpace Diagnostics Group Inc - pricing of an underwritten public offering of 12.5 million shares of its common stock.Interpace Diagnostics Group Inc - common warrants will be immediately exercisable at a price of $1.25 per share of common stock.  Full Article

Interpace Diagnostics qtrly EPS from continuing operations $0.42
Monday, 15 May 2017 08:30am EDT 

May 15 (Reuters) - Interpace Diagnostics Group Inc :Interpace diagnostics group reports first quarter 2017 financial results, business progress and recent accomplishments.Q1 revenue rose 14 percent to $3.5 million.Interpace diagnostics group inc qtrly earnings per share from continuing operations $0.42.  Full Article

Interpace Diagnostics eliminates long term secured debt
Thursday, 20 Apr 2017 08:08am EDT 

April 20 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics eliminates long term secured debt.Interpace Diagnostics - on April 18, 2017 a institutional investor exchanged $3.5 million secured note for a $3.5 million secured convertible note issued by co.Interpace Diagnostics- converted all of co's remaining long-term secured outstanding debt into common stock, no longer has any secured debt outstanding.  Full Article

Interpace Diagnostics announces European patent approval for underlying technology of its thyramir microrna classifier
Monday, 3 Apr 2017 08:10am EDT 

Interpace Diagnostics Group Inc : Interpace Diagnostics announces European patent approval for underlying technology of its thyramir microrna classifier .Interpace Diagnostics Group Inc says plans to validate and enforce this intellectual property in select European countries going forward.  Full Article

BRIEF-Interpace Diagnostics says Q3 sales up 27 pct

* Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments